BiotechTV

?????????????????????? ????????: Miami based Galatea Bio Inc. raised $25M today to expand its 'Galatea Global Biobank', an initiative to sequence 10 million participants worldwide, with a focus on individuals of non-European ancestry. Founder and CEO Carlos D. Bustamante tells BiotechTV's AI Correspondent, Ryan Flinn, about the biobank and why it is important to better understand how diseases can have different profiles across diverse populations. Plus, how AI will play a role in this work. Full video: https://lnkd.in/gJnZDR7i BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills

?????????????? ?????? ????????????????????: Gallop Oncology's CEO Luba Greenwood, J.D. on the importance of the Sisterhood, the Massachusetts life sciences ecosystem, and Gallop's work. Interviewed by Normunity CEO Rachel W. Humphrey, MD at MassBio's 2025 State of Possible Conference, Luba explains how the Biotech CEO Sisterhood arms members with important information, she shares the impression of the Massachusetts ecosystem she has gained as a MassBio board member, and also describes the effort against cancer at Gallop that motivates her each day. Full video: https://lnkd.in/gqvJF6fq BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills

?????????? ???? ????????????????: Winner of the MassBioDrive Startup of the Year Award last year, the Co-Founder and CEO of Eascra Biotech describes developing nanoparticles as a delivery vehicle for therapies. Mari Anne Snow describes the advantages she sees nanoparticles having over current modalities like viral vectors, LNPs, and others. Full video: https://lnkd.in/gB4uE5Pg BiotechTV's coverage of the State of Possible Conference is brought to you by MassBio. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills

?????????? ???? ????????????????: Atlas Venture's Bruce Booth shares his take on the current state of biotech and what it takes to get through difficult times for the industry as an investor and for companies. He describes the 14th fund that Atlas raised at the end of last year, which was $450 million. Plus, his take on the environment, regulatory changes, China's impact on the sector, and improving biopharma's image. Full video: https://lnkd.in/geFQKjsM BiotechTV's coverage of the State of Possible Conference is brought to you by MassBio. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills

?????????? ???? ????????????????: On the one-year anniversary of the spin-out of Seaport Therapeutics, Daphne Zohar describes the Glyph platform that powers it, and her thoughts on running depression trials. She describes the idea of leveraging Glyph to achieve oral dosing of medicines in cases where it would not be possible or tolerable. Plus, the lead clinical program, allopregnanolone, how the company thinks about avoiding high placebo responses in trials, and other programs. Full video: https://lnkd.in/gFapDPzH BiotechTV's coverage of the State of Possible Conference is brought to you by MassBio. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | Klein Hersh | Savills

?????????? ???? ????????????????: Beam Therapeutics' CEO John Evans discusses the company's recent alpha-1 antitrypsin deficiency data, what's ahead for sickle cell disease, and the current environment for biotech. He describes the nine patient dose ascending data in AAT deficiency that was historic for being the industry's first in-vivo proof of concept of a gene editor. Plus, what's next for that program and sickle cell, and the decision to do an "over the wall" financing. Full video: https://lnkd.in/g2Z_Eg8d BiotechTV's coverage of the State of Possible Conference is brought to you by MassBio. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills

?????????? ???? ????????????????: Cigall Kadoch discusses her pioneering work in chromatin regulation that has led to Foghorn Therapeutics Inc.. She describes the science behind chromatin and gene regulation, previews upcoming preclinical data the company will have at AACR for its lead SMARCA2 program (partnered with Lilly), and discusses what she would like to see out of future phase 1 data. Full video: https://lnkd.in/g7AJyCEK BiotechTV's coverage of the State of Possible Conference is brought to you by MassBio. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills

?????????? ???? ????????????????: Kymera Therapeutics' Founder and CEO Nello Mainolfi talks protein degradation, his take on recent industry data, and updates on the company's programs, including a new one to come He gives a brief overview of this approach, comments on recent competitor data in cancer, and highlights Kymera's STAT6 and TYK2 programs. Full video: https://lnkd.in/gs7Y6E92 BiotechTV's coverage of the State of Possible Conference is brought to you by MassBio. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills

?????????? ???? ????????????????: Office of Massachusetts Governor Maura Healey discusses keeping the state on top in life sciences, global competition, and more. She describes the efforts that government is making to support medical research in the area, shares her thoughts on competition in science and for jobs from China, and her thoughts on how the industry can improve its messaging. Full video: https://lnkd.in/ej8gxChH BiotechTV's coverage of the State of Possible Conference is brought to you by MassBio. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills

?????????? ???? ????????????????: Strand Therapeutics Co-Founder & CEO Jacob Becraft talks mRNA and getting into the clinic with the company's first program He describes the intratumoral IL-12 program that is in the clinic today, and the preclinical progress Strand is making on its other programs. Plus, his thoughts on the current public perception of mRNA. Full video: https://lnkd.in/gxWKxQe3 BiotechTV's coverage of the State of Possible Conference is brought to you by MassBio. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills